

RECEIVED
CENTRAL FAX CENTER**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****JUL 16 2009**

In re Patent Application of

BIRCH, P. et al.

Atty. Ref.: ARC-117-524

Serial No. 10/508,336

TC/A.U.: 1617

Filed: December 1, 2004

Examiner: Ramachandran, U.

For: BUPRENORPHINE FORMULATIONS FOR INTRANASAL DELIVERY

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Your petitioners, IONIX PHARMACEUTICALS LIMITED, a corporation having an office and place of business at 418 Cambridge Science Park Milton Road, Cambridge, United Kingdom CB4 0PA and ARCHIMEDES DEVELOPMENT LIMITED, a corporation having an office and place of business at Albert Einstein Centre Nottingham Science and Technology Park, University Boulevard, Nottingham, United Kingdom NG7 2TN represent that they are the assignees as recorded in an assignment at Reel 016147/Frame 0550 and Reel 018452/Frame 0745, of all right, title and interest in and to Application Serial No. 10/508,336, filed December 1, 2004, for BUPRENORPHINE FORMULATIONS FOR INTRANASAL DELIVERY.

Your petitioners hereby disclaim the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from Application Serial No. 11/798,384 and hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to such patent granted on the above-identified application shall be the same as the legal title to any patent issuing from Application Serial No. 11/798,384, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Petitioners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from Application Serial No. 11/798,384 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The evidentiary documents accompanying this document or referred to above have been reviewed by the undersigned and it is certified that to the best of the assignees' knowledge and belief, title is in the assignees seeking to take action.

Check either box 1 or 2 below, as appropriate.


1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

2. ☒ The undersigned is an attorney or agent of record.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**IONIX PHARMACEUTICALS LIMITED
ARCHIMEDES DEVELOPMENT LIMITED**

By: _____


Arthur R. Crawford
Assignees' Attorney

Date: _____

July 16, 2009

☒ **Terminal disclaimer fee under 37 C.F.R. § 1.20(d) included.** If missing, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140.

RECEIVED
CENTRAL FAX CENTER

JUL 16 2009

Petitioners do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from Application Serial No. 11/798,384 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The evidentiary documents accompanying this document or referred to above have been reviewed by the undersigned and it is certified that to the best of the assignees' knowledge and belief, title is in the assignees seeking to take action.


Check either box 1 or 2 below, as appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.
2. ☒ The undersigned is an attorney or agent of record.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

IONIX PHARMACEUTICALS LIMITED
ARCHIMEDES DEVELOPMENT LIMITED

By: _____


Arthur R. Crawford
Assignees' Attorney

Date: _____

July 16, 2009

☒ Terminal disclaimer fee under 37 C.F.R. § 1.20(d) included. If missing, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140.